Navigation Links
Diuretics excel in drug comparison trial involving hypertension/metabolic syndrome

HOUSTON(Jan. 28, 2008)Diuretics were associated with reduced heart disease in a drug comparison trial involving 23,077 people with both high blood pressure and the metabolic syndrome, a cluster of risk factors for heart disease, report researchers from The University of Texas School of Public Health and Case Western Reserve University in the Jan. 28 issue of the Archives of Internal Medicine, one of the JAMA/Archives journals. The cardiac benefits connected with diuretics were particularly pronounced in blacks, who have a high incidence of high blood pressure or hypertension.

In hypertensive patients with metabolic syndrome, initial treatment for hypertension should include a diuretic, said senior author Barry Davis, M.D., Ph.D., professor of biostatistics and the director of the Coordinating Center for Clinical Trials at the UT School of Public Health. Diuretics are preferred over other major classes of blood pressure medications to prevent one or more forms of cardiovascular disease.

High blood pressure is one of the risk factors included in the metabolic syndrome along with diabetes or pre-diabetes, excessive belly fat, high triglyceride levels, or low levels of high-density lipoprotein (good cholesterol). It is estimated that about 40 percent of adults age 60 years or older can be classified as having the metabolic syndrome.

According to Davis, the James W. Rockwell Professor of Public Health, diuretics, also known as water pills, offered greater protection against cardiovascular disease including heart failure, and were at least as effective for lowering blood pressure when compared to three other classes of blood pressure medications. The newer medications tend to produce better glucose and cholesterol values but the diuretics tend to generate better patient outcomes, he said.

This is an important study that provides a new insight into diuretic therapy for blood pressure control, particularly in patients with the metabolic syndrome who are subject to heart failure, said K. Lance Gould, M.D., professor in the Division of Cardiology at the UT Medical School at Houston.

While the primary endpoint showed no difference between drug treatment groups, subset analysis of the metabolic syndrome showed less heart failure when diuretics are used. This subset analysis emphasizes the value of diuretic treatment in patients with the metabolic syndrome who are subject to heart failure, said Gould, the Martin Bucksbaum Distinguished University Chair.

Diuretics lower blood pressure by reducing fluid from blood. The other classes of blood pressure medication tested during the trial included: calcium channel blockers which relax blood vessels; ACE inhibitors which prevent the formation of a hormone which causes blood vessels to narrow; and alpha blockers, which reduce nerve impulses that constrict vessels.

Among patients with the metabolic syndrome (7,327 black and 15,750 white patients), the calcium channel blocker, ACE inhibitor and alpha-blocker had higher rates of heart failure compared with the diuretic; the ACE inhibitor and the alpha-blocker also had an increased risk of combined cardiovascular disease.

The latest findings stem from a landmark investigation based at the UT School of Public Health, which in 2002 established that diuretics were as good or better than three other classes of medications for high blood pressure during a multi-center, randomized, double-blind, clinical trial. The investigation is called ALLHAT - Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Also contributing to the study from the UT School of Public Health were Sara Pressel, M.S., a faculty associate in biostatistics and co principal investigator of ALLHAT, and Charles Baimbridge, a graduate student in biostatistics.

This study once again demonstrates that thiazide-type diuretics are an effective and inexpensive therapy in all patients at risk for heart disease, regardless of ethnicity or metabolic status. The robust size of this study confirms their conclusions, said Philip R. Orlander, M.D., professor and interim chair in the Department of Medicine at the UT Medical School at Houston.

Diuretics were thought to be poor first choices for individuals with diabetes or the metabolic syndrome because of their known adverse impact on lipid profiles and glucose. One of the major contributions of the ALLHAT study is to disprove this hypothesis. The results of this study should be immediately adopted into clinical practice, Orlander said.


Contact: Robert Cahill
University of Texas Health Science Center at Houston

Related medicine news :

1. Diuretics Best for Hypertension and Metabolic Syndrome
2. Einstein honors Dr. Stanley Nathenson with Marshall S. Horwitz Faculty Prize for Research Excellence
3. Health Options, Inc.s BlueMedicare HMO Earns NCQA Excellent Rating
4. Brown named Center of Excellence in Geriatric Medicine and Training
5. Alzheimers Foundation of America Awards Excellence in Dementia Care Status to First Adult Day Center, More Long-Term Care Settings
6. Developing Excellence in Alliance
7. Bridges to Excellence Announces New Implementation Programs for Health Plans and Additions to Board of Directors
8. Hospice Caring, Inc. Earns Seal of Excellence and Elects New Board Member
9. Mayo Clinics Dr. Ronald C. Petersen Awarded Leon Thal Prize for Excellence in Dementia Research
10. Sharp HealthCare Receives 2007 Presidential Award for Quality and Performance Excellence
11. Center For Excellence to Fund Analysis of Michigan State Retiree Health Care Reforms
Post Your Comments:
Related Image:
Diuretics excel in drug comparison trial involving hypertension/metabolic syndrome
(Date:11/25/2015)... Rouge, LA (PRWEB) , ... November 25, 2015 , ... ... in the United States District Court of Connecticut on behalf of a home health ... behalf of all current or former home health care workers employed by Humana, Inc., ...
(Date:11/25/2015)... ... 2015 , ... Dental professionals who would like to become more proficient on ... Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held on ... co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to ...
(Date:11/25/2015)... ... 2015 , ... On November 23rd 2015 Cozy Products, a division ... business. Cozy Products explains what this means for business moving forward. , The Tri ... Products business model: to sell personal heaters that reduce energy consumption, are economical and ...
(Date:11/25/2015)... Evanston, IL (PRWEB) , ... November 25, 2015 ... ... homage to six decades of music, friendships, and learning in its 65th Anniversary ... be held Dec. 5-6. , For 65 years, Brillianteen has been ...
(Date:11/25/2015)... Missouri (PRWEB) , ... November 25, 2015 , ... ... HEAL, will provide scholarships for people struggling with eating disorders as a result ... from the second annual event, held at Fox Run Golf Club in Eureka, ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 AAIPharma ... planned investment of at least $15.8  Million to ... Wilmington, NC . The expansion will ... to meet the growing demands of the pharmaceutical ... site expansion will provide up to 40,000 ...
(Date:11/25/2015)... -- Henry Schein, Inc., the world,s largest provider of health ... animal health practitioners, will unveil at the Greater New ... Pavilion , which brings together for the first time ... help any practice or laboratory enter the digital age. ... of experts appearing at the Pavilion. --> ...
(Date:11/25/2015)... 25, 2015  Trovagene, Inc. (NASDAQ: TROV ), ... Chief Executive Officer Antonius Schuh, Ph.D., is scheduled to ... Annual Piper Jaffray Healthcare Conference. th ... Palace Hotel in New York ... Mr. Schuh will be available for one-on-one meetings during ...
Breaking Medicine Technology: